Cipla rose 0.95% to Rs 527.05 at 09:18 IST on BSE after the company received the Establishment Inspection Report from the USFDA, indicating closure of the inspection of Goa manufacturing facility.
The announcement was made after market hours yesterday, 4 April 2019.Meanwhile, the S&P BSE Sensex was up 105.85 points, or 0.27% to 38,790.57
On the BSE, 22,000 shares were traded in the counter so far compared with average daily volumes of 6.68 lakh shares in the past two weeks. The stock had hit a high of Rs 532.90 and a low of Rs 527 so far during the day.
Cipla said that following the inspection by the United States Food and Drug Administration (USFDA) at the Goa manufacturing facility from 21 to 28 January 2019, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection.
Cipla's consolidated profit after tax fell 17% to Rs 332 crore on 2% rise in total revenue from operations to Rs 4008 crore in Q3 December 2018 over Q3 December 2017.
Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in home markets of India, South Africa, North America, and key regulated and emerging markets.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
